Emergent BioSolutions Inc.
EBS · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $1,044 | $1,049 | $1,118 | $1,774 |
| % Growth | -0.5% | -6.1% | -37% | – |
| Cost of Goods Sold | $668 | $689 | $645 | $980 |
| Gross Profit | $375 | $360 | $473 | $793 |
| % Margin | 36% | 34.3% | 42.3% | 44.7% |
| R&D Expenses | $71 | $111 | $188 | $235 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $299 | $357 | $340 | $349 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $115 | $618 | $115 | -$132 |
| Operating Expenses | $484 | $1,086 | $643 | $452 |
| Operating Income | -$109 | -$726 | -$170 | $341 |
| % Margin | -10.4% | -69.2% | -15.2% | 19.2% |
| Other Income/Exp. Net | -$34 | -$5 | -$49 | -$38 |
| Pre-Tax Income | -$143 | -$731 | -$219 | $303 |
| Tax Expense | $48 | $29 | -$7 | $84 |
| Net Income | -$191 | -$761 | -$212 | $220 |
| % Margin | -18.3% | -72.5% | -18.9% | 12.4% |
| EPS | -3.6 | -14.85 | -4.47 | 4.1 |
| % Growth | 75.8% | -232.2% | -209% | – |
| EPS Diluted | -3.6 | -14.85 | -4.47 | 4.06 |
| Weighted Avg Shares Out | 53 | 51 | 50 | 54 |
| Weighted Avg Shares Out Dil | 53 | 51 | 50 | 54 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $71 | $88 | $37 | $35 |
| Depreciation & Amortization | $106 | $121 | $125 | $118 |
| EBITDA | $53 | -$47 | $16 | $504 |
| % Margin | 5.1% | -4.5% | 1.4% | 28.4% |